Drug intelligence / Profile preview

LJM716 + trastuzumab

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LJM716 + trastuzumab is a combination therapy consisting of two monoclonal antibodies targeting different components of the HER signaling pathway. LJM716 (elgemtumab) is a fully human anti-HER3 IgG1 monoclonal antibody that binds a conformational epitope that traps HER3 in the inactive conformation, preventing both ligand-induced and ligand-independent activation of HER3. Trastuzumab is a well-established HER2-targeted monoclonal antibody. This combination aims to overcome resistance mechanisms in HER2-positive cancers by simultaneously inhibiting HER2 and HER3 signaling pathways.

Other names: elgemtumab + trastuzumab

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on LJM716 + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LJM716 + trastuzumab.

Explore the full profile